Premium Company Profile - Celgene
Premium Company Profile - Celgene - New Research Report on Companies and Markets
© companiesandmarkets.com
15.11.2008 00:02:02 www.companiesandmarkets.com adds new report - Premium Company Profile - Celgene
(live-PR.com) - www.companiesandmarkets.com/Summary-Company-Prof ..
Introduction
Celgene is engaged in the discovery, development, and commercialization of therapies for the treatment of cancer and immunological diseases. Among seven marketed products, the company´s lead product is Revlimid, an analog of thalidomide that is approved by the FDA for the treatment of MDS patients with the 5q chromosomal deletion and for the treatment of relapsed/refractory myeloma.
Scope
Contains corporate strategy, value
chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company´s major contributor to revenue growth during 2002-2006 was product sales which increased at an absolute growth of +$689 million during the period
During fiscal 2006, the company generated approximately 90.3% of total revenues from product sales. Sales of Thalomid were $433 million during the year whereas Revlimid provided $321 million contributing collectively 84% of the total revenues in 2006
Celgene´s biggest contributor to sales growth out to 2010 will be revenues from Revlimid sales. This is mainly due to the expectation that Revlimid will eventually become the most preferred therapy for multiple myeloma
Reasons to Purchase
Access all the important information and analysis on a company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
Introduction
Celgene is engaged in the discovery, development, and commercialization of therapies for the treatment of cancer and immunological diseases. Among seven marketed products, the company´s lead product is Revlimid, an analog of thalidomide that is approved by the FDA for the treatment of MDS patients with the 5q chromosomal deletion and for the treatment of relapsed/refractory myeloma.
Scope
Contains corporate strategy, value
|
|
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company´s major contributor to revenue growth during 2002-2006 was product sales which increased at an absolute growth of +$689 million during the period
During fiscal 2006, the company generated approximately 90.3% of total revenues from product sales. Sales of Thalomid were $433 million during the year whereas Revlimid provided $321 million contributing collectively 84% of the total revenues in 2006
Celgene´s biggest contributor to sales growth out to 2010 will be revenues from Revlimid sales. This is mainly due to the expectation that Revlimid will eventually become the most preferred therapy for multiple myeloma
Reasons to Purchase
Access all the important information and analysis on a company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
| Author: |
